Bioactive analogs of neurotensin: Focus on CNS effects

Mona Boules; Paul Fredrickson; Elliott Richelson

doi:10.1016/j.peptides.2005.12.018

Bioactive analogs of neurotensin: Focus on CNS effects

Mona Boules, Paul Fredrickson, Elliott Richelson

Neuroscience

Research output: Contribution to journal › Review article › peer-review

53 Scopus citations

Abstract

Neurotensin (NT) is a 13-amino acid neuropeptide found in the central nervous system and in the gastrointestinal tract. It is closely associated anatomically with dopaminergic and other neurotransmitter systems, and evidence supports a role for NT agonists in the treatment of various neuropsychiatric disorders. However, NT is readily degraded by peptidases, so there is much interest in the development of stable NT agonists, that can be injected systemically, cross the blood-brain barrier (BBB), yet retains the pharmacological characteristics of native NT for therapeutic use in the treatment of diseases such as schizophrenia, Parkinson's disease and addiction.

Original language	English (US)
Pages (from-to)	2523-2533
Number of pages	11
Journal	Peptides
Volume	27
Issue number	10
DOIs	https://doi.org/10.1016/j.peptides.2005.12.018
State	Published - Oct 2006

Keywords

Neurotensin
Neurotensin analogs
Neurotensin antagonists
Neurotensin receptors

ASJC Scopus subject areas

Biochemistry
Physiology
Endocrinology
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.peptides.2005.12.018

Cite this

@article{d6391fbc03c148ddb4b16ebeac00b197,

title = "Bioactive analogs of neurotensin: Focus on CNS effects",

abstract = "Neurotensin (NT) is a 13-amino acid neuropeptide found in the central nervous system and in the gastrointestinal tract. It is closely associated anatomically with dopaminergic and other neurotransmitter systems, and evidence supports a role for NT agonists in the treatment of various neuropsychiatric disorders. However, NT is readily degraded by peptidases, so there is much interest in the development of stable NT agonists, that can be injected systemically, cross the blood-brain barrier (BBB), yet retains the pharmacological characteristics of native NT for therapeutic use in the treatment of diseases such as schizophrenia, Parkinson's disease and addiction.",

keywords = "Neurotensin, Neurotensin analogs, Neurotensin antagonists, Neurotensin receptors",

author = "Mona Boules and Paul Fredrickson and Elliott Richelson",

note = "Funding Information: Supported by Mayo Foundation for Medical Education and Research.",

year = "2006",

month = oct,

doi = "10.1016/j.peptides.2005.12.018",

language = "English (US)",

volume = "27",

pages = "2523--2533",

journal = "Peptides",

issn = "0196-9781",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Bioactive analogs of neurotensin

T2 - Focus on CNS effects

AU - Boules, Mona

AU - Fredrickson, Paul

AU - Richelson, Elliott

N1 - Funding Information: Supported by Mayo Foundation for Medical Education and Research.

PY - 2006/10

Y1 - 2006/10

N2 - Neurotensin (NT) is a 13-amino acid neuropeptide found in the central nervous system and in the gastrointestinal tract. It is closely associated anatomically with dopaminergic and other neurotransmitter systems, and evidence supports a role for NT agonists in the treatment of various neuropsychiatric disorders. However, NT is readily degraded by peptidases, so there is much interest in the development of stable NT agonists, that can be injected systemically, cross the blood-brain barrier (BBB), yet retains the pharmacological characteristics of native NT for therapeutic use in the treatment of diseases such as schizophrenia, Parkinson's disease and addiction.

AB - Neurotensin (NT) is a 13-amino acid neuropeptide found in the central nervous system and in the gastrointestinal tract. It is closely associated anatomically with dopaminergic and other neurotransmitter systems, and evidence supports a role for NT agonists in the treatment of various neuropsychiatric disorders. However, NT is readily degraded by peptidases, so there is much interest in the development of stable NT agonists, that can be injected systemically, cross the blood-brain barrier (BBB), yet retains the pharmacological characteristics of native NT for therapeutic use in the treatment of diseases such as schizophrenia, Parkinson's disease and addiction.

KW - Neurotensin

KW - Neurotensin analogs

KW - Neurotensin antagonists

KW - Neurotensin receptors

UR - http://www.scopus.com/inward/record.url?scp=33748754632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748754632&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2005.12.018

DO - 10.1016/j.peptides.2005.12.018

M3 - Review article

C2 - 16882457

AN - SCOPUS:33748754632

SN - 0196-9781

VL - 27

SP - 2523

EP - 2533

JO - Peptides

JF - Peptides

IS - 10

ER -

Bioactive analogs of neurotensin: Focus on CNS effects

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this